Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Imatinib Mesylate 17Dasatinib 8nilotinib 7Cytarabine 5Hydroxyurea 4ponatinib 3Peripheral Blood Stem Cell Transplantation 3Interferon-alpha 3bosutinib 2Surveys and Questionnaires 2Stem Cell Transplantation 2Radiotherapy 2Polymerase Chain Reaction 2Pioglitazone 2Idarubicin 2Cytogenetic Analysis 2Busulfan 2Antilymphocyte Serum 2thymoglobulin 1peginterferon alfa-2a 1flumatinib 1fludarabine phosphate 1Tyrosine Kinase Inhibitors 1Therapeutics 1Registries 1Psychiatric Rehabilitation 1Patient Reported Outcome Measures 1PF-114 1Mycophenolic Acid 1Mitoxantrone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × flumatinib × Clear all
NCT01503502 2013-04-10

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
150 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡